Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.35 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.32 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PHGDH | O43175 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509603 | 0.76 | CA12 (0.38) | CA12CA2CA9CA1SNCA | |
| SCHEMBL3182945 | 0.72 | SNCA (0.41) | CA12CA2CA9CA1SNCA | |
| SCHEMBL19629003 | 0.72 | GNAI3 (0.48) | — | |
| SCHEMBL1095829 | 0.71 | — | — | |
| SCHEMBL28883061 | 0.70 | SNCA (0.40) | CA12CA2CA9CA1SNCA | |
| SCHEMBL2763072 | 0.70 | SNCA (0.40) | CA12CA2CA9CA1SNCA | |
| SCHEMBL8535667 | 0.70 | SNCA (0.40) | CA12CA2CA9CA1SNCA | |
| SCHEMBL8694711 | 0.69 | GNAI3 (0.50) | CA12CA2CA9CA1SNCA | |
| SCHEMBL20258328 | 0.67 | CA12 (0.44) | CA12CA2CA9CA1ALDH1A1 | |
| SCHEMBL19503494 | 0.67 | GNAI3 (0.58) | CA12CA2CA9SNCAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530197-B2 | Analogs for the treatment of disease | INSILICO MEDICINE IP LIMITED (HK) | 2022-12-20 | — | — | US | disclosed |
| WO-2017201342-A1 | POLYNUCLEOTIDES ENCODING JAGGED1 FOR THE TREATMENT OF ALAGILLE SYNDROME | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530197-B2 | Analogs for the treatment of disease | MAP4K4, MAP4K5, MAP4K2 | CA12 4540/4885CA2 3134/4885CA9 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.